公开(公告)号：US11851679B2

公开(公告)日：2023-12-26

申请号：US16760006

申请日：2018-11-01

申请人： Juno Therapeutics, Inc.

发明人： Rupesh Amin ,  Aye Chen

IPC分类号： C12N5/0783 ,  C07K14/725 ,  C12N15/113 ,  C12N15/65 ,  C12N15/86

CPC分类号： C12N5/0636 ,  C07K14/7051 ,  C12N15/113 ,  C12N15/65 ,  C12N15/86 ,  C07K2319/03 ,  C12N2740/16043

摘要： Provided herein are reporter T-cells containing a reporter operably linked to the Nur77 locus. Also provided are methods for screening for an activity of a recombinant receptor, including those containing an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR), including assessing activity of a cell expressing the recombinant receptor based on a detectable expression of a reporter molecule responsive to a signal through the intracellular signaling region of the recombinant receptor. In some embodiments, the activity assessed is an antigen-dependent or an antigen-independent activity. In some embodiments, the methods can be used to screen a plurality of reporter cells each containing a nucleic acid molecule encoding a candidate recombinant receptor, e.g. CAR, and assessing such cells for one or more property or activity. The methods can be high-throughput. Also provided are reporter cells, cell compositions, nucleic acids and kits for use in the methods.

公开(公告)号：US11066475B2

公开(公告)日：2021-07-20

申请号：US16178571

申请日：2018-11-01

申请人： Juno Therapeutics, Inc. ,  Memorial Sloan Kettering Cancer Center

发明人： Blythe D. Sather ,  Eric L. Smith ,  Rupesh Amin ,  Aye Chen ,  Kimberly Harrington ,  Collin Hauskins ,  Erik Hess ,  Cyr De Imus ,  Jon Jones ,  Audrey Olshefsky ,  Stefan Ponko ,  Ruth Salmon ,  Semih Tareen ,  Rebecca Wu ,  Yan Chen ,  Steven M. Shamah ,  Csaba Pazmany ,  Jui Dutta-Simmons ,  Mariana Cota Stirner ,  Melissa Works

IPC分类号： A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  A61P35/00 ,  A61K39/395 ,  C07K14/705 ,  C12Q1/6848 ,  A61K39/00 ,  A61K38/00

摘要： Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.